Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Employees - 60, CEO - Deborah L. Birx, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -7.73, Piotroski Score(max is 10): 2, Working Capital: $-112565000, Total Assets: $80790000, Retained Earnings: $-350561000, EBIT: -12094000, Total Liabilities: $150293000, Revenue: $6868000

- Current Price $ - Analyst Target Price $